3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
9
Sarcoma
5
Recurrence
5
Neoplasm Metastasis
5
Lymphoma
5
Breast Neoplasms
5
Endometrial Neoplasms
4
Ovarian Neoplasms
3
Solid Tumors
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Solid Tumor
1
Primary Myelofibrosis
1
Osteosarcoma
1
Myelodysplastic Syndromes
1
Liposarcoma
1
Leukemia
1
Leiomyosarcoma
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Bone Neoplasms
1
Advanced Cancers
1
Interventions
Surveys and Questionnaires
4
pazopanib
3
Erlotinib Hydrochloride
3
Cetuximab
3
Vorinostat
2
Oxaliplatin
2
Bevacizumab
2
Azacitidine
2
temsirolimus
1
satraplatin
1
ridaforolimus
1
ixazomib
1
X-Rays
1
Videotape Recording
1
Valproic Acid
1
Trastuzumab
1
Sugars
1
Sorafenib
1
Platinum
1
Pemetrexed
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Lenalidomide
1
Lapatinib
1
LY 2275796
1
Injections, Subcutaneous
1
Fluorouracil
1
Everolimus
1
Curcumin
1
Crizotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Cancers
×
ridaforolimus
×
Clear all
NCT00836927
2019-02-18
MK-8669-038
Merck Sharp & Dohme LLC
Phase 2
Terminated
7 enrolled
13 charts